Naus N - Search Results

1

Outcome after treatment for sebaceous carcinoma: A multicenter study.

In 't Veld EH, Keizer R, Post N, Versteeg J, Verdijk R, Naus N, Relyveld G, Crijns M, Smith M, Grünhagen D, Wakkee M, Paridaens D, Zavrakidis I, Mooyaart A, van Akkooi A, Strauss D, Verhoef C, Wouters M, Hayes A, van Houdt W. In 't Veld EH, et al. Among authors: naus n. J Surg Oncol. 2022 Mar;125(4):730-735. doi: 10.1002/jso.26774. Epub 2022 Jan 6. J Surg Oncol. 2022. PMID: 34990031 Free PMC article.

2

Orbital chondrosarcoma developing in a patient with Paget disease.

Mooy CM, Naus NC, de Klein A, van den Bosch WA, Paridaens DA. Mooy CM, et al. Among authors: naus nc. Am J Ophthalmol. 1999 May;127(5):619-21. doi: 10.1016/s0002-9394(98)00405-x. Am J Ophthalmol. 1999. PMID: 10334366

3

Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization.

Naus NC, Verhoeven AC, van Drunen E, Slater R, Mooy CM, Paridaens DA, Luyten GP, de Klein A. Naus NC, et al. Clin Cancer Res. 2002 Feb;8(2):534-9. Clin Cancer Res. 2002. PMID: 11839674

4

Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients.

Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo HB, Luyten GP, de Klein A. Kilic E, et al. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2253-7. doi: 10.1167/iovs.04-1460. Invest Ophthalmol Vis Sci. 2005. PMID: 15980208

5

Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.

van Gils W, Lodder EM, Mensink HW, Kiliç E, Naus NC, Brüggenwirth HT, van Ijcken W, Paridaens D, Luyten GP, de Klein A. van Gils W, et al. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4254-62. doi: 10.1167/iovs.08-2033. Epub 2008 Jun 14. Invest Ophthalmol Vis Sci. 2008. PMID: 18552379

6

Chromosome 3 intratumor heterogeneity in uveal melanoma.

Mensink HW, Vaarwater J, Kiliç E, Naus NC, Mooy N, Luyten G, Brüggenwirth HT, Paridaens D, de Klein A. Mensink HW, et al. Among authors: naus nc. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):500-4. doi: 10.1167/iovs.08-2279. Epub 2008 Sep 29. Invest Ophthalmol Vis Sci. 2009. PMID: 18824727

7

Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results.

Muller K, Naus N, Nowak PJ, Schmitz PI, de Pan C, van Santen CA, Marijnissen JP, Paridaens DA, Levendag PC, Luyten GP. Muller K, et al. Among authors: naus n. Radiother Oncol. 2012 Feb;102(2):219-24. doi: 10.1016/j.radonc.2011.06.038. Epub 2011 Aug 22. Radiother Oncol. 2012. PMID: 21864922

8

Histopathologic, immunohistochemical, ultrastructural, and cytogenetic analysis of oncocytic uveal melanoma.

Verdijk RM, van den Bosch T, Naus NC, Paridaens D, Mooy CM, de Klein A. Verdijk RM, et al. Arch Ophthalmol. 2011 Nov;129(11):1501-2. doi: 10.1001/archophthalmol.2011.312. Arch Ophthalmol. 2011. PMID: 22084225 No abstract available.

9

Multiplex ligation-dependent probe amplification equals fluorescence in-situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma.

Vaarwater J, van den Bosch T, Mensink HW, van Kempen C, Verdijk RM, Naus NC, Paridaens D, Brüggenwirth HT, Kiliç E, de Klein A. Vaarwater J, et al. Melanoma Res. 2012 Feb;22(1):30-7. doi: 10.1097/CMR.0b013e32834e6a67. Melanoma Res. 2012. PMID: 22157614

10

Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis.

van den Bosch T, van Beek JG, Vaarwater J, Verdijk RM, Naus NC, Paridaens D, de Klein A, Kiliç E. van den Bosch T, et al. Invest Ophthalmol Vis Sci. 2012 May 14;53(6):2668-74. doi: 10.1167/iovs.11-8697. Invest Ophthalmol Vis Sci. 2012. PMID: 22427574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page